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MitochondrialNuclear receptors (NRs) are important pharmacological targets for a number of diseases, including cancer and
metabolic disorders. To unmask the direct role of NR function it is fundamental to ﬁnd the NR targets. During
the last few years several NRs have been shown to affect microRNA expression, thereby modulating protein
levels. The farnesoid X receptor (FXR), the main regulator of bile acid (BA) homeostasis, also regulates
cholesterol, lipid and glucose metabolism. Here we used, for the ﬁrst time, a proteomics approach on mice
treated with a FXR ligand to ﬁnd novel hepatic FXR targets. Nineteen spots with a more than two-fold
difference in protein amounts were found by 2D-DIGE and 20 proteins were identiﬁed by MALDI-TOF MS as
putative novel FXR targets. Themost striking feature of the protein list was the great number of mitochondrial
proteins, indicating a substantial impact of FXR activation onmitochondrial function in the liver. To examine if
the differences found in the proteomics assay reﬂected differences at the mRNA level, a microarray assay was
generated on hepatic samples from wild type and FXR−/− mice treated with a FXR ligand and compared to
vehicle treatment. At least six proteins were shown to be regulated only at a post-transcriptional level. In
conclusion, our study provides the impetus to include proteomic analysis for the identiﬁcation of novel targets
of transcription factors, such as NRs. This article is part of a Special Issue entitled: Translating nuclear
receptors from health to disease.receptor; BA, bile acid; FXR−/−,
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Nuclear receptors (NRs) are important pharmacological targets for
treatment of a number of diseases, including cancer and metabolic
disorders [1]. Great efforts are made to ﬁnd substances that are speciﬁc
to a NR subtype or that affect only certain aspects of the NR function [2].
To understand all the effects and possible side effects of NR activation or
repression it is fundamental to ﬁnd the NR targets. Since NRs are
transcription factors, it is natural to look for tissue speciﬁc expression
patterns and their target genes by gene expression proﬁling [3,4]. A lot
of information has been gained from such studies. However, bearing in
mind the diverseways of regulation of RNAs and proteins, including the
effects of microRNAs on mRNA translation and degradation, maybe a
proteomics approach should be applied as well. Indeed, during the lastfew years several NRs have been shown to affect microRNA expression,
thereby modulating protein levels [5–10].
The farnesoid X receptor (FXR), the main regulator of bile acid
(BA) homeostasis [11–13], also regulates cholesterol, lipid and
glucose metabolism [14]. The importance of FXR for the metabolic
homeostasis in the gut-liver axis has been revealed in whole body and
tissue speciﬁc FXR loss-of-function (FXR−/−) mouse models [15–17].
Furthermore, FXR has been shown to play a role in processes such as
liver regeneration [18], carcinogenesis [19–21], inﬂammation and
bacterial overgrowth in the intestine [22,23]. There are therapeutic
potentials for selective FXR modulators in diseases such as the
metabolic syndrome, diabetes, gallstone disease, hypertriglyceride-
mia, steato-hepatitis and colon cancer [14,21]. A recent study of
genomic FXR binding in mouse liver and intestine suggests a greater
number of FXR target genes than is known thus far [24]. Also a high
degree of tissue-speciﬁc binding was revealed, where only 11% of the
binding sites were shared between the tissues, indicating a high
degree of tissue-speciﬁc effects of FXR activation. The hepatic FXR
target genes found up till now encode proteins involved in BA, lipid
and glucose metabolism as well as in the detoxiﬁcation of xenobiotics
[25]. In a recent study FXR has also been shown to inhibit the
expression of a microRNA, miR-34a [8].
To ﬁnd hepatic FXR targets we used, for the ﬁrst time, a proteomics
approach with mice treated with the potent FXR ligand 6-ethyl
chenodeoxycholic acid (6-ECDCA or INT-747) [26]. In addition, a
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in the proteomics assay reﬂected differences at the mRNA level.
2. Materials and methods
2.1. Animals and treatments
Ten weeks old wild type C57BL/6J male mice and FXR−/− C57BL/6J
male mice were treated with 10 mg/kg/day INT-747 (Intercept
Pharmaceuticals) or only the vehicle, 1% methylcellulose, by gavages
for at least threedays. The animalswere fastedovernight andgiven their
last gavages 3 h before the sacriﬁce. The liver sampleswere snap-frozen
in liquid nitrogen and kept at−80 °C until used. The Ethical Committee
of the Consorzio Mario Negri Sud approved this experimental set-up,
whichwas also certiﬁed by the ItalianMinistry of Health accordingwith
internationally accepted guidelines for the animal care.
2.2. Proteomic analysis
2.2.1. Liver protein extraction for proteomic analysis
Individual mouse liver samples were ground into powder under
liquid nitrogen, dissolved in a buffer containing 5 M urea, 2 M thiourea,
2% (w/v) CHAPS, 2% (w/v) Zwittergent 3-10 detergent (Calbiochem,
Merck Biosciences, Darmstadt, Germany) 50 mM DTT (Sigma Aldrich,
Milano, Italy) and protease inhibitor cocktail set III (Calbiochem). After a
centrifugation at100,000g for 30 minat12 °C thepelletswere discarded
and the supernatants taken as the cytosol fraction. The protein content
was determined by ETTAN™ procedure, using a protein assay kit from
GE Healthcare (Chalfont St. Giles, Bucks, UK).
2.2.2. Two-dimensional difference gel electrophoresis (2D-DIGE) and
quantitative gel image analysis
Five vehicle and ﬁve INT-747 samples (each 50 μg of protein) were
labeled separately with either 200 pmol Cy3 or Cy5, and the internal
standard (25 μg of each of the ten samples) was labeled with Cy2. One
vehicle, INT-747 and standard sample forming a set of Cy2, Cy3 and
Cy5 labeled samples were combined for each of ﬁve gels and were
diluted in the rehydration solution, composed of 5 M urea, 2 M
thiourea, 2% (w/v) CHAPS, 2% (w/v) Zwittergent, 40 mMDTT and 0.5%
IPG buffer for pH 3–10 linear gradient (GE Healthcare). Isoelectric
focusing (IEF) was carried out on immobilized IPG strips with a broad
pH 3–10 linear gradient, by using an IPGphor Isoelectric Focusing
System (GE Healthcare). After a rehydration step at 30 V for 16 h,
focusing started at 200 V. The voltage was increased step by step to
1000 V, then gradually up to 8000 V and kept constant for further 5 h
for a total 46,000 Vh. Following IEF, individual protein strips were
reduced by rocking for 15 min in a solution containing 6 M urea,
50 mM Tris–HCl, pH 8.8, 30% (v/v) glycerol, 2% (w/v) SDS, 1% DTT.
Proteins were subsequently alkylated by replacing DTT with 100 mM
iodoacetamide for 15 min. The strips were placed on the top of 12.5%
SDS-PAGE (160×160×1 mm) and run at 10 mA, for molecular size
electrophoresis. Protein size was determined by running standard
protein markers (Rainbow, GE Healthcare), in the range of 14.3–
220.0 kDa.
Images were visualized using the pharos-FX imager from Bio-Rad.
The gels were scanned using a 488 nm laser and an emission ﬁlter of
530 nm BP (band Pass) 40, a 532 nm laser and an emission ﬁlter of
695 nm DF (discriminating ﬁlter) 50, a 635 nm laser and 695 nm DF 55
emission ﬁlter to acquire the Cy2, Cy3, and Cy5 image respectively. All
gels were scanned at 200 μm resolution. Images were then processed
using the PD-Quest software (Bio-Rad) protocol. Protein spots were
matched and gels were normalized using the internal standard present
in all gels.
An overall total of around 1500 protein spots were visualized in the
present study and a p-valueb0.05 (Student's t-test) was consideredstatistically signiﬁcant. Only the spots showing at least a two-fold
difference were further analyzed.
2.2.3. Protein identiﬁcation by MALDI-TOF MS analysis
Anadditional gelwasmadeusing300 μg of total proteinpooled from
each of the ﬁve vehicle and INT-747 samples analyzed run under
conditions identical to the analytical gels except that the proteins were
unlabeled (non DIGE). Selected protein spots were in situ digested and
analyzed by MALDI-TOF MS. Brieﬂy, protein bands were excised from
SDS-PAGE and after washing, cysteins were reduced with DTT and
alkylated with iodoacetamide. Gels were digested in situ by incubation
with sequencing-grade trypsin (Promega, Madison,WI, USA) in 40 mM
ammoniumbicarbonate under slight shaking on a thermomixer at 37 °C
overnight [27]. The reactionwas stoppedwithH2O/TFA0.1%at 30 °C, for
15 min. Tryptic peptides were extracted, desalted with ZipTip C18
columns (Millipore Corp, Bedford, MA, USA), eluted and crystallized
in 50% (v/v) ACN/H2O saturated solution of alfa-cyano-4-hydroxy-
cinnamic acid. Peptide mass spectra were obtained by a time-of-ﬂight
mass spectrometer (Reﬂex IV®, Bruker Daltonics, Bremen, Germany),
equippedwith a nitrogen laserwith an emissionwavelength of 337 nm.
Mass spectra were acquired in positive ion Reﬂectron-mode with
delayed extraction and an accelerating voltage of 20 kV. An external
calibration was performed for each measurement, using a mixture of
seven standard peptides (average mass accuracy better than 20 ppm).
All mass spectra were acquired using a minimum number of 250 laser
shots. Spectrawere internally calibratedwith trypsin autolysis products.
Peptide matching and protein searches were performed submitting
peptide mass lists to database search on NCBInr and/or SWISS PROT,
using the MASCOT and ProFound search engines. The main search
parameters were as follows: no restriction on molecular weight and
isoelectric point (MW and pI); taxonomy, mause; one missed cleavage
allowed; carboxymethylation of cystein; oxidation of methionine; 50–
100 ppm peptide mass tolerance. Proteins listed as signiﬁcant matches
in MASCOT were considered when a threshold score allowing a pb0.05
was achieved.
2.2.4. Western blot analysis
Western blot analysis was performed on pooled mouse liver
samples,ﬁve in eachgroup, processed asdescribed above. Total proteins
were quantiﬁed by ETTAN™ procedure, using a protein assay kit from
GE Healthcare (Chalfont St. Giles, Bucks, UK).
For one-dimensional (1-DE) gel electrophoresis, samples of cytosol
fractions were dissolved in SDS sample buffer, composed of 12.5 mM
Tris–HCl, pH 6.8, 1% SDS, 10% glycerol, 0.025% bromophenol blue, boiled
for 10 min, and applied to 12.5% (w/v) SDS-PAGE. Following 1-DE
separation, proteinswere transferred to nitrocellulose and after transfer,
the nitrocellulose blots were checked by Ponceau red staining to ensure
an homogeneous transfer efﬁciency. The blots were then probed with a
primary antibodyanti-GSTM1(kindlyprovidedbyDr. B. Favaloro, Ce.S.I.,
University G. D'Annunzio, Chieti, Italy), ATP5A (C-15):sc-49162 anti-
body , Laminin-R antibody (G-7):sc-74531,(Santa Cruz Biotechnology
Inc, Santa Cruz, CA, USA), AnnexinV antibody (ab 14196) Abcamplc,330
Cambridge science park, Cambridge CB4 OFL, UK. Blots were visualized
by ECL chemiluminescence detection system (GEHealthcare) according
to the manufacturer. Protein abundance was quantiﬁed by densitomet-
ric analysis, with Quantity ONE software (Bio-Rad) and the results
normalized against β-Actin.
2.3. Real-time quantitative PCR (RT-qPCR)
Total RNA was extracted using QIAzol (Qiagen) and the integrity of
the RNA was assessed on a formaldehyde gel. cDNA was synthesized
from total RNA by High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) after DNase I treatment using the DNA-free Kit
from Ambion. Relative amounts of Shp and cyclophilin mRNA were
obtained on a 7500 Fast Real-Time PCR System machine (Applied
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levels were normalized to the amounts of cyclophilin mRNA. The
primers used are available upon request.
2.4. Microarray
Expression proﬁling was performed using the Illumina Mouse MG-
6V2 BeadArray Expressionwith biological duplicates for each treatment
and animal genotype. The RNA integrity was assessed using the BioRad
Experion System. Ampliﬁcation was made with 500 ng of total RNA
using the Illumina TotalPrep RNA Ampliﬁcation kit (Ambion). The
quantity and quality of biotin-UTP incorporated cRNAwas also assessed
using the BioRad Experion System. 1.5 μg ampliﬁed cRNA from each
sample was hybridized to the arrays according to the manufacturer's
guidelines. The data were analyzed using the GenomeStudio software.
3. Results
In a 2D-DIGE assay, comparing hepatic protein samples from INT-
747 with vehicle treated mice, 19 spots were more than two-fold
different in protein levels (Fig. 1A, Tables S1 and S2). For seven spots
the amount of proteinwas higher in the INT-747 samples compared to
vehicle, while in the rest it was reduced by the FXR ligand treatment.
The proteins in the spots were identiﬁed by MALDI-TOF MS (Table 1).
In spot 8302 two different proteins were found, argininosuccinate
synthase and 3-ketoacylCoA thiolase. It is therefore unclear which
protein, or if possibly both were down regulated in response to the
FXR activation. In this study we also compared hepatic samples from
FXR−/− mice, treated with the semi-synthetic bile acid INT-747 or
vehicle, and no differences in protein amounts could be detected for
any of the proteins in Table 1 (data not shown). This comparison was
made as an objective control for non-FXR mediated effects that could
relate to the weak agonistic effect of INT-747 on the membrane TGR5
receptor [28].
For four of the proteins, ATP synthase, annexin A5, the laminin
receptor and glutathione S-transferase, the differences in protein
levels were veriﬁed by the use of Western blot (Fig. 1B). All four
proteins showed a similar regulation as were seen by DIGE, but with a
lower fold difference. This indicated a successful outcome of the
proteomics analysis but even so, the results for the other proteins in
Table 1 should be conﬁrmed by Western blot to be considered as true
FXR targets. All in all, 20 different proteins were identiﬁed as being
potential novel FXR targets in the proteomic analysis and four of these
were veriﬁed as bona ﬁde FXR targets by Western blot.
Subsequently, a microarray assay was carried out on hepatic
samples from wild type and FXR−/− mice treated with INT-747 or
vehicle to examine if the differences found in the proteomics assay
reﬂected differences at the mRNA level. To ascertain FXR activation by
the INT-747 treatment, themRNA levels of the known FXR target gene
Nr0b2, also called Shp, encoding the orphan NR small heterodimer
partner (SHP), were assessed by RT-qPCR (Fig. S1). Samples with a
high Shp mRNA expression after INT-747 treatment were chosen for
the subsequent array experiment. Sequences corresponding to the
pyruvate carboxylase (Pcx), regucalcin (Rgn), ribosomal protein SA
(Rpsa) and sarcosine dehydrogenase (Sardh) genes (equivalent to the
protein spots 4712, 202, 301 and 5702, respectively) yielded signals
on the arrays that were below background levels, and were therefore
considered as not detectable (Table 1). Comparing the array results of
INT-747 treated with vehicle treated mice, no differences of at least
1.5-fold could be detected for the genes encoding the proteins
identiﬁed as FXR targets in the proteomic analysis. In the comparison
of wild type with FXR−/− mice, both INT-747 treated, four mRNAs
turned out at least 2-fold different; annexin A5 (Anxa5), glutamate
dehydrogenase 1 (Glud1), glutathione S-transferase, mu 1 (Gstm1)
and 4-hydroxyphenylpyruvic acid dioxygenase (Hpd) (corresponding
to protein spots 108, 6408, 8106 and 6304 respectively). Ten mRNAsdiffered at least 1.5-fold, adding acetyl-Coenzyme A acyltransferase 2
(Acaa2), argininosuccinate synthetase 1 (Ass1), catalase (Cat), gluta-
mate oxaloacetate transaminase 2 (Got2), ornithine aminotransferase
(Oat) and sulﬁte oxidase (Suox) (equivalent to protein spots 8302, 8302,
8401, 9207, 3304 and 2405 respectively) to the list. The less stringent
1.5-fold criteria still leaves six genes that were not considered
differentially expressed, suggesting different amounts of protein after
FXR ligand treatmentdue to other regulatorymechanismsbeside effects
on transcription. These sequences correspond to the genes arginase
(Arg1), ATP synthase, H+ transporting, mitochondrial F1 complex,
alpha subunit 1 (Atp5a1), carbamoyl-phosphate synthetase 1(Cps1),
heat shock protein 8 (Hspa8), malate dehydrogenase 2 (Mdh2) and
tubulin, alpha 1C (Tuba1c/Tuba6) (equivalent to protein spots 5206/
5207, 8408, 5811, 1613, 9208 and 408, respectively).
Finally, the microarray results for four of the genes, corresponding
to the FXR targets corroborated byWestern blot (Atp5a1, Anxa5, Rpsa
and Gstm1), were veriﬁed by RT-qPCR showing a very good
correlation with the microarray data (Fig. 1C), with the exception of
Rpsa/Lamr which was not detectable in the microarray analysis.
4. Summary and conclusions
Gene expression analysis has been the method of choice to identify
NR targets. Very few studies of proteomic analysis of NR targets have
been published thus far. However, considering regulatory mechanisms
acting directly on the protein level, such as the effects of microRNAs,
proteomics could be of great importance also for the NR ﬁeld. In fact, in
the present study, none of the proteins found to be potential FXR targets
in the proteomics assay have previously been shown to be regulated by
FXR.Oneof themost striking features of theprotein list generatedbyour
proteomics assay is the great number of mitochondrial proteins,
indicating a novel and substantial impact of FXR activation on
mitochondrial function in the liver. Another noticeable feature is the
number of proteins involved in the urea cycle andmetabolism of amino
groups.
Two of the proteins veriﬁed as bona ﬁde FXR targets have been
implicated in hepatocellular carcinoma (HCC), the laminin receptor and
glutathione-S transferase. The laminin receptor is an extracellularmatrix
glycoprotein involved in a wide variety of biological processes such as
cell adhesion, differentiation, migration andmetastasis. Increased levels
of the laminin receptor have been correlated to HCC [29–31]. For gluta-
thione S-transferase, an enzyme detoxifying electrophilic compounds
by conjugating them with glutathione, null mutations have been linked
with an increase in a number of cancers, including HCCwhen combined
with alcohol intake [32,33]. ATP synthase subunit alpha is a part of the
mitochondrial ATP synthase that catalyzes ATP synthesis and involve-
ment of FXR activation in the oxidative phosphorylative process has not
been shown before. Also ATP synthase has been shown to be connected
with liver cancer. Yamada et al. found increased levels of ATP synthase in
hepatoblastomasas compared tonormal liver tissue [34]. AnnexinA5 is a
calcium-dependent phospholipid binding protein inhibiting phospholi-
pase A2 and protein kinase C, and is widely used as a marker for
apoptosis. Future studies should focus on dissecting the translational
relevance of the present data in terms of in vivometabolic pathways.
At least six of the proteins found in the proteomics assay seem to be
regulated at a post-transcriptional level. It is possible, or perhaps even
likely, that other proteins in Table 1 are post-transcriptionally regulated
since the criteria we set to discover differences in mRNA amounts were
at a low stringency. The comparison between thewild typemice treated
or not with the FXR agonist did not reveal any differences at the mRNA
level for the proteins in Table 1, even at a fold difference of 1.5. In fact,
none of the mRNAs showed a difference greater than 1.2. Only the
comparison between the wild type and FXR−/− mice showed
differences in mRNA amounts. However, the comparison between
wild type and FXR−/− animals is a more artiﬁcial set-up, relating to the
presence and absence of FXR, rather than the actual activation of the
Fig. 1. Identiﬁcation of potential FXR targets. A) Hepatic cytosolic protein samples from wild type mice treated with INT-747 or vehicle were compared in a 2D-DIGE. Four examples
of spots differentially expressed are shown and the proteins were identiﬁed by MALDI-TOF MS. The pH and molecular weights scales are indicated in the ﬁgure. B) Western blot on
four of the proteins identiﬁed as potential FXR targets in the proteomics analysis. Pooled hepatic cytosolic protein samples fromwild type mice treated with INT-747 or vehicle were
compared (n=5). The quantiﬁed results were normalized against β-actin. C) RT-qPCR on four genes corresponding to proteins identiﬁed as potential FXR targets in the proteomics
analysis. Five individual samples were analyzed for each treatment and the error bars represent the standard deviation. *pb0.05, Student's t-test.
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selected for a high FXR activation by assessing the mRNA levels of the
FXR target gene Shp, to ascertain the identiﬁcation of FXR targets
regulated on the mRNA level. Selecting samples with a high Shp
induction created a bias toward ﬁnding transcriptionally regulated FXR
targets, which could mean an incidence of false positives. Thus, the
absence of differences in mRNA levels, in the INT-747 versus vehicle
treated wild type mice, for the proteins identiﬁed as novel targets, inthose selected samples, further increases the value of our ﬁnding.
Recently a microRNA, miR-34a, was shown to be inhibited by FXR [8]
suggesting one possible mechanism for the post-translational regula-
tion of FXR targets. The FXR induced protein SHPwas shown to interact
with p53, thereby inactivating the transactivation of the miR-34a
promoter, leading to an increase in Sirtuin 1.
In conclusion, we could ﬁnd novel FXR targets by a proteomic
approach. Since at least six of these were indicated to be post-
Table 1
Proteomics quotients for the identiﬁcation of potential FXR targets along with corresponding mRNA quotients.
Spot Protein ID Protein name Sequence
Coverage
(%)
Mascot
Score
INT-747/
vehicle
(protein)
Gene Symbol Gene ID INT-747/
vehicle
(mRNA)
Wt /FXR-/-
(mRNA) 
GI:6680748 ATP Syntase subunit alpha, mitochondrial 39 141 + 14 Atp5a1 11946 1.1 1.0
5702 GI:20149748 Sarcosine dehydrogenase, mitochondrial 47 146 + 4 Sardh 192166 ND ND
301 GI:171948782 Laminin Receptor/40S ribosomal protein SA 45 121 + 3 Rpsa (Lamr) 16785 ND ND
GI:6678469 Tubulin alfa-1C Chain 34 125 + 3 22146 1.0 − 1.4
2405 GI:74024924 Sulfite Oxidase, mitochondrial 46 139 + 3 Suox 211389 − 1.0 − 1.5
202 GI:6677739 Regucalcin 45 142 + 2 Rgn 19733 ND ND
GI:7106255 Arginase-1 46 140 + 2 Arg1 11846 1.1 − 1.2
4712 GI:251823978 Pyruvate Carboxylase, mitochondrial isoform 2 37 223 − 2 Pcx 18563 ND ND
6408 GI:148692928 Glutamate dehydrogenase 1, mitochondrial 36 124 − 2 Glud1 14661 1.1 − 2.0
8401 GI:157951741 Catalase 44 198 − 3 Cat 12359 − 1.1 − 1.7
6304 GI:33859486 4-hydroxyphenylpyruvate dioxygenase 36 139 − 4 Hpd 15445 − 1.1 − 2.3
9207 GI:192050
Aspartate aminotransferase, mitochondrial/
Glutamate oxaloacetate transaminase 2
33 152 − 4 Got2 14719 1.2 − 1.8
GI:42542422 Heat shock protein 8/Heat shock cognate 71 kDa 41 124 − 5 Hspa8 15481 − 1.1 − 1.0
8106 GI:6754084 Glutathione S-transferase Mu 1 68 142 − 5 Gstm1 14862 1.1 − 3.1
8302 GI:6996911 Argininosuccinate synthase 55 149 − 6 Ass1 11898 1.1 − 1.7
8302 GI:148677565 Acetyl-coenzyme A acyltransferase 2 52 119 − 6 Acaa2 52538 − 1.0 − 1.6
GI:124248512 Carbamoyl-phosphate Synthase, mitochondrial 37 359 − 7 Cps1 227231 1.1 − 1.4
108 GI:6753060 Annexin A5 40 139 − 8 Anxa5 11747 1.1 − 2.0
3304 GI:8393866 Ornithine aminotransferase, mitochondrial 42 178 − 8 Oat 18242 − 1.0 − 1.5
GI:89574115 Mitochondrial malate dehydrogenase 2 NAD 40 163 − 70 Mdh2 17448 1.1 − 1.3
408
5206
8408
1613
5811
9208
Tuba1c (Tuba6) 
Gray shading, FXR targets showing a difference at the protein level but not at the mRNA level after FXR ligand treatment. ND, mRNA levels below background level in the
microarray analysis, i.e. not detectable.
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been found by gene expression techniques. Our laboratory is currently
investigating the physiological relevance of the new FXR target
pathways in different in vivomodels. The knowledge of the FXR driven
regulatory pathways is of great importance since soon a novel FXR
ligand will probably enter the clinic. Perhaps more importantly, our
study provides the impetus to include proteomic analysis for the
identiﬁcation of novel targets of transcription factors, such as NRs.
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